IMUC: ImmunoCellular Therapeutics, Ltd. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 5:45 PM After-hours top gainers, as of 5:15 p.m.: PDII +26.9%. NSPH +20.1%. III +11.6%. TTWO +4.1%. NTI +2.9%.
After-hours top losers: MOSY -9.4%. ATAX -4.6%. SPH -4.3%. WES -3.9%. IMUC -3.6%. Comment! [On the Move]
Thursday, May 9, 6:04 PM ImmunoCellular (IMUC): Q1 EPS of -$0.10 misses by $0.02. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, April 3, 5:35 PM After-hours top gainers, as of 5:15 p.m.: CCG +8%. ANV +5%. AVEO +4%. GFI +3%. VALE +2%.
After-hours top losers: SFUN -6%. IMUC -3%. CPWR -3%. LSE -3%. ROC -2%. Comment! [On the Move]
Thursday, March 7, 8:30 AM Northwest Biotherapeutics (NWBO +2%) expects to complete the enrollment of a 312-patient Phase III trial for its Glioblastoma multiforme brain cancer drug by Q1 or early Q2 next year. NW Bio says its recruitment is faster or more efficient than that for rival drugs, including for treatments from Celldex (CLDX), Immunocellular (IMUC) and Agenus (AGEN). (PR) 1 Comment [Healthcare]
Tuesday, March 5, 6:07 PM After-hours top gainers, as of 5:30 p.m.: HCI +11%. ELX +10%. HNR +8%. PAY +5%. BPZ +4%.
After-hours top losers: AVAV -22%. HLS -11%. NAVB -7%. JMBA -6%. IMUC -5%. Comment! [On the Move]
Tuesday, March 5, 4:34 PM ImmunoCellular Therapeutics (IMUC): Q4 EPS of -$0.01 beats by $0.07. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 4, 8:25 AM ImmunoCellular Therapeutics (IMUC) receives a patent covering its ICT-121 immunotherapeutic cancer vaccine, which targets CD133, an important cancer stem cell marker that is "commonly overexpressed on a broad range of solid tumors." These include brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. The patent includes claims covering composition of matter and methods of use. (PR) Comment! [Healthcare]
Monday, January 7, 8:02 AM ImmunoCellular Therapeutics (IMUC) provides an update about the various cancer vaccines it's developing, saying it expects the Data Safety Monitoring Committee to conduct an interim safety and futility analysis of the Phase IIb trial of ICT-107, which targets glioblastoma antigens and cancer stem cells, early this year. (PR) Comment! [Healthcare]
Monday, December 3, 2012, 5:48 PM After-hours top gainers, as of 5:15 p.m.: ESIO +11.7%. PETS +5.6%. DWA +5.2%. IMUC +3.2%. PACR +3%.
After-hours top losers: PBY -6.4%. PFPT -5.9%. DST -3.9%. PDLI -3.2%. GRMN -2.4%. Comment! [On the Move]
Monday, December 3, 2012, 4:23 PM ImmunoCellular (IMUC) +7% AH after announcing Andrew Gengos, until recently the CEO of private Neuraltus Pharmaceuticals, is its new CEO. Chief scientific officer John Yu had been serving as interim CEO since August, when former chief Manish Singh stepped down. Comment! [Healthcare, On the Move]
Thursday, October 18, 2012, 1:36 PM ImmunoCellular Therapeutics (IMUC -13.8%) slides after pricing its secondary offering of 10M shares at $2.10, a 13% discount to yesterday's close. The company also is offering warrants to purchase as many as 4.5M additional shares. It plans to use the proceeds for the ongoing clinical development of its brain cancer treatment and lead pipeline product, ICT-107, as well as for general corporate purposes. The company had 40.6 million shares outstanding as of August.
6 Comments [Healthcare, On the Move]
Thursday, October 18, 2012, 12:45 PM Midday top 10 gainers: CYBI +81%. OEH +26%. BWEN +23%. IESC +20%. ETH +20%. GIVN +18%. AEGR +17%. VIMC +16%. WCC +14%. CHCI +13.
Top 10 Losers: ALGN -24%. MNKD -23%. MLNX -21%. CYTR -19%. GORO -16%. IMUC -14%. RCON -13%. LXRX -11%. BCOM -11%. UFPI -11%. Comment! [On the Move]
Thursday, October 18, 2012, 9:10 AM Premarket gainers: GIVN +13%. WCC +11%. SVU +9%. JNPR +7%. NVAX +7%. MGM +6%. AEGR +5%.
Losers: MNKD -25%. CYTR -20%. ALGN -20%. IMUC -18%. LXRX -16%. MLNX -15%. GORO -14%. CDR -7%. SCSS -7%. VRNG -6%. 1 Comment [On the Move]
Thursday, September 6, 2012, 9:30 AM ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product. 5 Comments [Healthcare, Quick Ideas, On the Move]
Thursday, September 6, 2012, 9:10 AM Premarket gainers: IMUC +14%. MW +11%. OREX +10%. ARCT +8%. SHLD +7%. NAV +7%.
Losers: OCZ -30%. PAY -11%. WCRX -10%. Comment! [On the Move]
Tuesday, August 21, 2012, 9:10 AM Premarket gainers: DEXO +35%. URBN +16%. NDSN +10%. PRAN +7%. PSTI +6%.
Losers: IMUC -15%. BBY -10%. VHC -8%. Comment! [On the Move]

IMUC ImmunoCellular Therapeutics, Ltd.

IMUC

ImmunoCellular Therapeutics, Ltd.